WO2020046029A1 - 유방암 진단용 바이오마커 및 이의 용도 - Google Patents
유방암 진단용 바이오마커 및 이의 용도 Download PDFInfo
- Publication number
- WO2020046029A1 WO2020046029A1 PCT/KR2019/011108 KR2019011108W WO2020046029A1 WO 2020046029 A1 WO2020046029 A1 WO 2020046029A1 KR 2019011108 W KR2019011108 W KR 2019011108W WO 2020046029 A1 WO2020046029 A1 WO 2020046029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- expression level
- protein
- fragment
- serpina6
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- a composition, kit for diagnosing breast cancer or mammary cancer, and a method for predicting the possibility of diagnosing or developing breast cancer using the same are provided.
- Human breast or mammary cancer is a malignant tumor with the second highest incidence of female cancer.
- the causes of breast cancer vary, but only about 20% of the known causes. The remaining 80% of the cause is unknown, but the opinion is likely to be caused by an external environment. Diseases caused by the external environment are so diverse that it is difficult to explain them as one cause. Therefore, a complex external environment is considered to be a major cause of breast cancer. Diseases caused by external environmental causes cannot be predicted and prevented, and since the treatment process is performed only after the diagnosis of the disease is made, there is a problem that the cost, duration and recovery time are considerable.
- Companion animals for example companion dogs
- the development of mammary gland cancer in dogs may mean the likelihood of developing breast cancer in humans (Sahabi K et al., J Vet Sci. 2018 Mar 31; 19 (2): 162-171).
- kits for diagnosing breast cancer are provided.
- a method of diagnosing breast cancer or a method of providing information for diagnosing breast cancer is provided.
- compositions for diagnosing breast cancer comprising an agent measuring an expression level of a gene encoding a protein selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6, or an expression level of the protein or fragment thereof.
- the PGLYRP2 is a peptidoglycan recognition protein 2, N-acetylmuramoyl-L-alanine amidase, HMFT0141, PGLYRPL, PGRP-L, PGRPL, TAGL It may also be called analogous protein, tagL, tagL-alpha, or tagl-beta.
- PGLYRP2 is Uniprot No. Amino acid sequence represented by Q96PD5.
- the GP1BA is a platelet glycoprotein Ib alpha chain, BDPLT1, BDPLT3, BSS, CD42B, CD42b-alpha, DBPLT3, GP1B, GPIbA, VWDP, GPIbalpha, glycoprotein Ib platelet alpha subunit, or It may also be referred to as protein Ib platelet subunit alpha.
- Glycoprotein Ib is a platelet surface membrane glycoprotein consisting of alpha and beta chain heterodimers linked by disulfide bonds. Glycoprotein Ib can function as a receptor for von Willebrand factor (VWF).
- the GP1BA is a Uniprot No. for humans. It may include the amino acid sequence represented by P07359. GP1BA is Uniprot No. Amino acid sequence represented by Q28256.
- SERPING1 may also be called serpin family G member 1, C1-inhibitor, C1 esterase inhibitor, C1IN, C1INH, C1NH, HAE1, or HAE2.
- the SERPING1 may inhibit the complement system to prevent continuous activation, and may inhibit not only the complement system but also the protease of the fibrinolytic, coagulation, and kinin pathways.
- the SERPING 1 is for Uniprot No. It may include an amino acid sequence represented by P05155.
- SERPING1 is the case of Uniprot No. It may include the amino acid sequence represented by F1PYX9.
- SERPINA6 may also be called serpin family A member 6, Transcortin, or corticosteroid-binding globulin (CBG).
- CBG corticosteroid-binding globulin
- the SERPINA6 may be an alpha-globulin protein having corticosteroid-binding activity.
- SERPINA6 in the case of human Uniprot No. It may include the amino acid sequence represented by P08185.
- SERPINA6 in the case of Uniprot No. It may include an amino acid sequence represented by F1PHS2.
- the fragment may be an immunogenic polypeptide as part of the protein.
- the “gene” refers to a nucleic acid encoding the protein.
- the expression level of a gene can be the expression level of mRNA encoding the protein or fragment thereof.
- the expression level of mRNA may be a relative amount or an absolute amount of mRNA. Measuring the expression level of the gene may be to measure the amount of mRNA.
- expression level refers to the amount of protein or the amount of transcript.
- the expression level may be a relative proportion of the protein or fragment thereof, or transcript.
- an increase in expression level may be an increase in the amount of protein or transcript compared to a negative control.
- the agent may be an antibody or antigen binding fragment thereof, or an aptamer that specifically binds to the protein or fragment thereof.
- the antibody may be a polyclonal antibody or a monoclonal antibody.
- the term "antibody” may be used interchangeably with the term "immunoglobulin".
- the antibody may be a polyclonal antibody or a monoclonal antibody.
- the antibody may be a full length antibody.
- the antigen binding fragment refers to a polypeptide comprising an antigen binding site.
- the antigen binding fragment may be a single-domain antibody, Fab, Fab ', or scFv.
- the antibody or antigen-binding fragment may be attached to a solid support.
- the solid support is, for example, the surface of a metal chip, plate, or well.
- the aptamer may be a single strand of nucleic acid (DNA, RNA or modified nucleic acid) or peptide that specifically binds to the S1PR1 protein or fragment thereof.
- the agent may be a nucleic acid comprising a polynucleotide identical or complementary to a polynucleotide encoding the protein or fragment thereof.
- the nucleic acid may be a primer, probe, or antisense oligonucleotide.
- the primer, probe, or antisense oligonucleotide may be labeled with a fluorescent substance, chemiluminescent or radioisotope at its end or inside thereof.
- breast cancer refers to a cancer occurring in the breast and may be interchangeably referred to as "mammary tumor".
- mammary tumor For example, in humans it can be called breast cancer and in dogs and cats it can be called mammary cancer.
- the breast cancer may include mammary gland breast cancer, lobule breast cancer, or a combination thereof.
- the breast cancer includes cancers that occur in the epithelium of the milk ducts and lobes and cancers that occur in the stroma.
- diagnosis refers to determining a disease name and may include the name of the breast cancer, the condition of the disease, the stage, the etiology, the presence or absence of complications, prognosis, recurrence, and the like.
- the composition may be for diagnosing mammary tumors in dogs and breast cancers in humans simultaneously or sequentially.
- the composition can be used for diagnosing mammary gland cancer in dogs and then used to diagnose human breast cancer.
- kits for diagnosing breast cancer comprising an agent measuring the expression level of a gene encoding a protein selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6, or the expression level of the protein or fragment thereof.
- the PGLYRP2, GP1BA, SERPING1, and SERPINA6, genes, fragments, expression levels, agents, breast cancer, and diagnosis are as described above.
- the kit may further include a sample necessary for diagnosing breast cancer.
- the kit may comprise a solid support, or a substrate, a suitable buffer, a chromogenic enzyme, a secondary antibody labeled with a fluorescent substance, or a chromogenic substrate for immunological detection of an antibody, antigen binding fragment, or aptamer.
- the kit may comprise a polymerase, a buffer, a nucleic acid, a coenzyme, a fluorescent substance, or a combination thereof, for nucleic acid detection.
- the polymerase is for example Taq polymerase.
- Another aspect includes measuring the expression level of a gene encoding a protein selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6, or the expression level of said protein or fragment thereof in a biological sample isolated from a subject suspected of breast cancer; And comparing the measured expression level with the expression level of a normal control group.
- the PGLYRP2, GP1BA, SERPING1, and SERPINA6, genes, fragments, expression levels, agents, breast cancer, and diagnosis are as described above.
- the method comprises measuring the expression level of a gene encoding a protein selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6, or the expression level of the protein or fragment thereof, in a biological sample isolated from a subject suspected of breast cancer. Include.
- the subject may be a mammal, eg, a human, dog, cat, mouse, rabbit, horse, sheep, hamster, hedgehog, ferret, or guinea pig.
- the subject may be a subject suffering from or suspected of having breast cancer.
- the biological sample refers to a sample obtained from the individual.
- the biological sample is blood, plasma, serum, urine, mucus, saliva, tears, sputum, spinal fluid, pleural fluid, nipple aspirate, lymph, airway, intestinal fluid, urogenital fluid, breast milk, lymphatic system fluid, semen, cerebrospinal fluid, intratracheal system Body fluid, ascites, cystic tumor fluid, amniotic fluid, or a combination thereof.
- the measuring step includes incubating the biological sample with an antibody or antigen-binding fragment thereof, or aptamer specifically binding to a protein or fragment thereof selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6. can do.
- the measuring step is electrophoresis, immunoblotting, enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining, protein chip, immunoprecipitation, microarray, northern blotting, polymerase amplification reaction ( polymerase chain reaction (PCR), or a combination thereof.
- the electrophoresis may be SDS-PAGE, isoelectric point electrophoresis, two-dimensional electrophoresis, or a combination thereof.
- the PCR may be real time PCR or reverse transcription PCR.
- the method includes comparing the measured expression level with that of a normal control.
- normal control may be used interchangeably with the term “negative control”.
- the normal control may be an individual who has never had breast cancer or a healthy individual.
- the method may further comprise determining that the subject has breast cancer or is more likely to have breast cancer when the measured expression level is increased relative to the expression level measured in the normal control group.
- Another aspect includes measuring the expression level of a gene encoding a protein selected from the group consisting of PGLYRP2, GP1BA, SERPING1, and SERPINA6, or the expression level of said protein or fragment thereof in a biological sample isolated from a subject suspected of breast cancer; And comparing the measured expression level with the expression level of a normal control group to provide information for diagnosing breast cancer.
- the method may further comprise predicting the likelihood of developing breast cancer in a second individual through diagnosing the breast cancer in the individual.
- the individual ie, the first individual
- the companion animal may refer to an animal that lives in the same living environment with a human.
- the companion animal may be a dog, cat, mouse, rabbit, hamster, hedgehog, ferret, or guinea pig. Since one of the main causes of breast cancer is environmental factors, it is possible to diagnose breast cancer in a companion animal that lives in the same environment as a human and provide early diagnosis or provide information for breast cancer in a human guardian of a companion animal. have.
- a dog can diagnose a diagnosis of mammary cancer and predict the possibility of developing breast cancer in a person who is a guardian of a dog.
- breast cancer diagnosis, kit, and a method for diagnosing breast cancer using the same or a method for providing information for diagnosing breast cancer breast cancer can be diagnosed early.
- FIG. 1A and 1B are lists of proteins differentially expressed in mammary cancer blood samples and normal blood samples in dogs
- FIG. 1C is a list of proteins differentially expressed in breast cancer blood samples and normal samples in humans.
- FIG. 2A is a graph of Venn diagrams showing significantly increasing proteins in human breast cancer and dog mammary gland cancer.
- FIG. 2B is a list of proteins analyzed by BenDogram.
- Serum protein was obtained from the prepared blood sample, and the obtained protein was digested with trypsin (Promega).
- the digested peptide sample was purified using a C 18 column (Thermo Fisher Scientific Inc.). Purified peptides were calculated using raw mass spectrometry (Thermo Fisher Scientific Inc.) according to the mass of the peptide.
- Raw data were used to analyze proteins differentially expressed in mammary cancer blood samples and normal blood samples in dogs, or in breast cancer blood samples and normal blood samples in humans.
- Proteins differentially expressed in mammary cancer blood samples and normal blood samples in dogs are shown in FIGS. 1A and 1B.
- Proteins differentially expressed in breast cancer blood samples and normal samples in humans are shown in FIG. 1C.
- Example 1.1 to screen proteins commonly differentially expressed in mammary cancer blood samples and human breast cancer blood samples in dogs, proteins with expression levels increased by at least 1.2 fold over normal blood were screened.
- Proteins that significantly increased 1.2 times more than normal blood in human breast cancer and proteins that increased 1.2 times more than normal blood in dog's mammary cancer blood sample were analyzed by Venn diagram, and the list of proteins was shown in FIGS. 2A and 2B, respectively. Shown in
- the specific differentially expressed proteins in dogs ORM1, IGFBP1, PRDX1, PRDX4, KRT71, RPS27A, UBA52, UBBP4, UBC, KCTD12, ERAP1, HSPG2, LRG1, HSP90B1, ALB, CSF1, VCL, LOC100684663, LOC102155886, LOC476879, SAA1, CP, MGAM, CFP, RNPEP, CRP, SERPINA7, CPA3, CPB2, ITIH4, LCP1, PLS3, AMY2B, LOC480825, LOC607314, LOC608248, AAX3, LAD1, L3 LOC608247, GPX3, FCRL2, FCRL4, APOD, HIST1H2BA, MMP19, DSP, VTN, ALPP, PLTP, CRISP2, MST1, PSMA7, PSMA8, LOC100687054, LCAT, SELP, TTR, LYZ,
- RNASE7 RNASE7, PI16, CD44, AGT, PZP, ITIH3, C2, QSOX1, APCS, C4A, C4B, CLEC3B, IGKV, A18, CRISP3, ALCAM, AZGP1, SERPINA1, IGLV7-46, SERPINA4, AFM, CHL1, SELL, IGHG3, HBB, IGHV3-73, SERPINF2, IGHA1, S100A9, BTD, IGHA2, PPBP, PF4, PF4V1, FCN2, and F12.
- the proteins differentially expressed in human breast cancer and dog mammary cancer in common were found to be PGLYRP2, SERPING1, GP1BA, and SERPINA6.
- PGLYRP2, GP1BA, SERPING1, and SERPINA6 are common biomarkers differentially expressed in mammary gland cancer of dogs and human breasts.They detect these biomarkers and apply them to humans to diagnose mammary cancer in humans and to diagnose breast cancer in humans or breast cancer. It was confirmed that the onset can be predicted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
- PGLYRP2, GP1BA, SERPING1, 및 SERPINA6으로 이루어진 군으로부터 선택된 단백질을 암호화하는 유전자의 발현 수준, 또는 상기 단백질 또는 그의 단편의 발현 수준을 측정하는 제제를 포함하는 유방암 진단용 조성물.
- 청구항 1에 있어서, 상기 제제는상기 단백질 또는 그의 단편에 특이적으로 결합하는 물질은 항체 또는 이의 항원 결합 단편, 또는 앱타머; 또는상기 단백질 또는 이의 단편을 암호화하는 폴리뉴클레오티드와 동일하거나 또는 이에 상보적인 폴리뉴클레오티드를 포함하는 핵산인 것인 조성물.
- 청구항 2에 있어서, 상기 항체는 폴리클론 항체 또는 모노클론 항체인 것인 조성물.
- 청구항 2에 있어서, 상기 핵산은 프라이머, 프로브, 또는 안티센스 올리고뉴클레오티드인 것인 조성물.
- 청구항 1에 있어서, 상기 조성물은 개의 유선암(mammary tumor) 및 사람의 유방암(breast cancer)을 동시 또는 순차로 진단하기 위한 것인 조성물.
- PGLYRP2, GP1BA, SERPING1, 및 SERPINA6으로 이루어진 군으로부터 선택된 단백질을 암호화하는 유전자의 발현 수준, 또는 상기 단백질 또는 그의 단편의 발현 수준을 측정하는 제제를 포함하는 유방암 진단용 키트.
- 유방암이 의심되는 개체로부터 분리된 생물학적 시료에서 PGLYRP2, GP1BA, SERPING1, 및 SERPINA6으로 이루어진 군으로부터 선택된 단백질을 암호화하는 유전자의 발현 수준, 또는 상기 단백질 또는 그의 단편의 발현 수준을 측정하는 단계; 및상기 측정된 발현 수준을 정상 대조군의 발현 수준과 비교하는 단계를 포함하는, 유방암의 진단 방법.
- 청구항 7에 있어서, 상기 개체는 사람, 개, 고양이, 마우스, 토끼, 말, 양, 햄스터, 고슴도치, 페럿(ferret), 또는 기니 피그(guinea pig)인 것인 방법.
- 청구항 7에 있어서, 상기 생물학적 시료는 혈액, 혈장, 혈청, 소변, 점액, 타액, 눈물, 객담, 척수액, 흉수, 유두 흡인물, 림프액, 기도액, 장액, 비뇨생식관액, 모유, 림프계 체액, 정액, 뇌척수액, 기관계내 체액, 복수, 낭성 종양 체액, 양수액 또는 이들의 조합인 것인 방법.
- 청구항 7에 있어서, 상기 측정하는 단계는 상기 생물학적 시료와, PGLYRP2, GP1BA, SERPING1, 및 SERPINA6으로 이루어진 군으로부터 선택된 단백질 또는 그의 단편에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편, 또는 앱타머를 인큐베이션시키는 단계를 포함하는 것인 방법.
- 청구항 7에 있어서, 상기 측정하는 단계는 전기영동, 면역블로팅, 효소 결합 면역흡착 분석법(Enzyme-Linked Immunosorbent Assay: ELISA), 면역 조직 화학 염색, 단백질 칩, 면역침강, 마이크로어레이, 노던 블로팅, 폴리머라제 증폭 반응(polymerase chain reaction: PCR), 또는 이들의 조합으로 수행되는 것인 방법.
- 청구항 7에 있어서, 상기 측정된 발현 수준이 정상 대조군에서 측정된 발현 수준에 비해 증가한 경우, 상기 개체는 유방암에 걸리거나 유방암에 걸릴 확률이 높은 것으로 결정하는 단계를 더 포함하는 것인 방법.
- 유방암이 의심되는 개체로부터 분리된 생물학적 시료에서 PGLYRP2, GP1BA, SERPING1, 및 SERPINA6으로 이루어진 군으로부터 선택된 단백질을 암호화하는 유전자의 발현 수준, 또는 상기 단백질 또는 그의 단편의 발현 수준을 측정하는 단계; 및상기 측정된 발현 수준을 정상 대조군의 발현 수준과 비교하는 단계를 포함하는, 유방암을 진단하기 위해 정보를 제공하는 방법.
- 청구항 13에 있어서, 상기 개체의 유방암 진단을 통해 제2 개체의 유방암의 발병 가능성을 예측하는 단계를 더 포함하는 것인 방법.
- 청구항 14에 있어서, 상기 개체는 반려 동물이고 제2 개체는 사람인 것인 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0103034 | 2018-08-30 | ||
KR1020180103034A KR102128547B1 (ko) | 2018-08-30 | 2018-08-30 | 유방암 진단용 바이오마커 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020046029A1 true WO2020046029A1 (ko) | 2020-03-05 |
Family
ID=69645223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/011108 WO2020046029A1 (ko) | 2018-08-30 | 2019-08-30 | 유방암 진단용 바이오마커 및 이의 용도 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102128547B1 (ko) |
WO (1) | WO2020046029A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112680520A (zh) * | 2020-12-29 | 2021-04-20 | 北京大学 | Znf408在乳腺癌诊断及预后评估中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054271A1 (en) * | 2003-03-20 | 2007-03-08 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
KR20150061816A (ko) * | 2013-11-28 | 2015-06-05 | 한국기초과학지원연구원 | 혈액유래 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 |
US20160161492A1 (en) * | 2014-05-09 | 2016-06-09 | Ascendant Diagnostics, LLC | Methods Of Detecting Cancer |
US20180100201A1 (en) * | 2015-06-29 | 2018-04-12 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
-
2018
- 2018-08-30 KR KR1020180103034A patent/KR102128547B1/ko active IP Right Grant
-
2019
- 2019-08-30 WO PCT/KR2019/011108 patent/WO2020046029A1/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054271A1 (en) * | 2003-03-20 | 2007-03-08 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
KR20150061816A (ko) * | 2013-11-28 | 2015-06-05 | 한국기초과학지원연구원 | 혈액유래 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 |
US20160161492A1 (en) * | 2014-05-09 | 2016-06-09 | Ascendant Diagnostics, LLC | Methods Of Detecting Cancer |
US20180100201A1 (en) * | 2015-06-29 | 2018-04-12 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
"Developing Human Breast Cancer Diagnosis Technologies by Researching Companion Dog Breast Cancers", 4 July 2016 (2016-07-04), Retrieved from the Internet <URL:http://www.dailyvet.co.kr/news/academy/62560> * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112680520A (zh) * | 2020-12-29 | 2021-04-20 | 北京大学 | Znf408在乳腺癌诊断及预后评估中的应用 |
CN112680520B (zh) * | 2020-12-29 | 2022-09-20 | 北京大学 | Znf408在乳腺癌诊断及预后评估中的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR102128547B1 (ko) | 2020-06-30 |
KR20200025544A (ko) | 2020-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012506253A (ja) | 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法 | |
WO2017222221A1 (ko) | 포타슘 채널 단백질을 이용한 암 진단용 조성물 | |
WO2021210905A1 (ko) | 암의 예후 예측용 조성물 | |
WO2020256526A1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단 또는 신장이식 후 환자의 예후 예측을 위한 소변 엑소좀 바이오마커 | |
KR100721507B1 (ko) | 위암 진단 마커로서의 Mac-2BP | |
WO2020046029A1 (ko) | 유방암 진단용 바이오마커 및 이의 용도 | |
WO2015174585A1 (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 | |
WO2010085124A2 (ko) | 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측 | |
WO2011138955A1 (ja) | Siaα2-8Siaα2-3Galβ-R糖鎖を持つムチン1の分析方法 | |
KR102091747B1 (ko) | 유방암 진단용 바이오마커 및 이의 용도 | |
KR102018209B1 (ko) | 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법 | |
WO2020256530A1 (ko) | 신장이식 후 t세포 매개성 거부반응의 진단 또는 신장이식 후 환자의 예후 예측을 위한 소변 엑소좀 바이오마커 | |
KR101582416B1 (ko) | 프로합토글로빈을 이용한 간암 진단방법 | |
WO2020091237A1 (ko) | 비만 진단용 바이오마커 및 이의 용도 | |
EP4332242A1 (en) | Method for predicting prognosis of gastric cancer | |
KR102687116B1 (ko) | 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법 | |
WO2021172926A1 (ko) | 암의 진단용 조성물 | |
WO2020256529A1 (ko) | 신장이식 후 bk 바이러스 감염성 신병증의 진단 또는 신장이식 후 환자의 예후 예측을 위한 소변 엑소좀 바이오마커 | |
WO2024151138A1 (ko) | 엑소좀을 이용한 편평상피세포 폐암 진단 또는 예후 예측용 바이오마커 및 이의 용도 | |
KR102259708B1 (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
KR102259695B1 (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
WO2023177206A1 (ko) | 췌장암의 진단용 조성물 | |
WO2024101853A1 (ko) | 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트 | |
KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
WO2021137553A1 (ko) | 임신중독증 진단용 바이오마커 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19854838 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19854838 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19854838 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |